Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

940
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
940
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

512
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
512
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

209
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
209

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brexpiprazole for Agitation in Patients with Alzheimer's Dementia with and without Co-Occurring Psychosis: Post Hoc Analysis of Short- and Long-Term Trials.

Neuropsychiatric disease and treatment·2026
Same author

Dementia in Progressive Supranuclear Palsy: A Narrative Review.

Neurology and therapy·2026
Same author

Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders.

Nature aging·2025
Same author

Effect of Intensive Systolic Blood Pressure Control on Markers of Cerebral Small Vessel Disease by Age.

Hypertension (Dallas, Tex. : 1979)·2025
Same author

A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panel.

Postgraduate medicine·2025
Same author

Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years.

Alzheimer's & dementia (New York, N. Y.)·2025

Related Experiment Video

Updated: Jan 8, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

Fosgonimeton in mild-to-moderate Alzheimer's disease.

Anton P Porsteinsson1, Marwan Sabbagh2, Pierre N Tariot3

  • 1Alzheimer's Disease Care, Research and Education Program(AD-CARE), Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Journal of Alzheimer'S Disease Reports
|December 15, 2025
PubMed
Summary

Fosgonimeton did not significantly improve Alzheimer's disease symptoms in a Phase 2/3 trial. However, the drug showed potentially relevant biological activity and an acceptable safety profile, warranting further investigation into HGF pathway modulation.

Keywords:
Alzheimer's diseaseacetylcholinesterase inhibitoractivities of daily livingbiomarkersclinical trials/studiescognitive assessmentfosgonimetonglobal statistical testneuroprotectiveneurotrophic

More Related Videos

Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
05:54

Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials

Published on: May 10, 2024

2.0K
Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze
07:07

Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze

Published on: October 29, 2019

20.0K

Related Experiment Videos

Last Updated: Jan 8, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K
Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
05:54

Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials

Published on: May 10, 2024

2.0K
Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze
07:07

Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze

Published on: October 29, 2019

20.0K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Trials

Background:

  • Fosgonimeton is a small-molecule positive modulator of the neurotrophic hepatocyte growth factor (HGF) system.
  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline.

Purpose of the Study:

  • To evaluate the efficacy and safety of fosgonimeton in participants with mild-to-moderate Alzheimer's disease.
  • To assess the impact of fosgonimeton on cognitive and functional endpoints, as well as biomarkers.

Main Methods:

  • A randomized, placebo-controlled, Phase 2/3 trial (LIFT-AD) involving 287 participants with mild-to-moderate AD.
  • Participants received daily subcutaneous fosgonimeton (40 mg) or placebo, without concomitant acetylcholinesterase inhibitors.
  • Primary endpoint was the Global Statistical Test (GST) score; secondary endpoints included ADAS-Cog11, ADCS-ADL23, and NfL levels.

Main Results:

  • The trial did not meet its primary or secondary endpoints, with no significant differences between fosgonimeton and placebo groups.
  • Small, non-significant improvements favoring fosgonimeton were observed in ADAS-Cog11 and ADCS-ADL23.
  • Fosgonimeton demonstrated an acceptable safety profile, with serious adverse events balanced between groups; however, more participants discontinued due to AEs in the fosgonimeton group.

Conclusions:

  • Fosgonimeton did not significantly improve cognitive or functional outcomes in Alzheimer's disease patients.
  • The observed non-significant trends suggest potential biological activity of fosgonimeton, indicating that HGF pathway modulation may impact neurodegenerative processes.
  • Further research may explore the therapeutic potential of HGF pathway modulation in neurodegenerative diseases.